Skip to main content
Premium Trial:

Request an Annual Quote

IncellDx BioINK PD-L1 CTC Core Kit

IncellDx has launched its BioINK PD-L1 CTC Core Kit, a complete, pre-optimized tool to identify, enumerate, and quantify PD-L1 expression in circulating tumor cells. According to the firm, the kit includes the addition of a separate quantitative control cell cocktail — called OncoTect iO Control Cells — that combines PD-L1 positive epithelial cells, PD-L1 negative epithelial cells, and peripheral blood mononuclear cells. The tool allows labs to assess linearity and lower limits of detection for CTC enumeration with known quantities of cells in a lyophilized standard.

The firm's BioINK technology enables highly sensitive and specific quantification of protein or mRNA expression at a single-cell-by-cell resolution optimized for microfluidic chips. 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.